Abbott Laboratories has announced groundbreaking results from its REFLECT real-world studies, showcasing the significant impact of its FreeStyle Libre® continuous glucose monitoring (CGM) technology on reducing cardiovascular complications in individuals with diabetes. The studies reveal a 78% reduction in hospitalizations for cardiovascular disease among people with Type 1 diabetes who experienced prior severe low blood sugar episodes. Additionally, the technology is associated with an 80% reduction in heart-related hospitalizations for those without a prior history of cardiovascular issues. Similar benefits were observed in adults with Type 2 diabetes on insulin. These findings highlight the transformative potential of Libre technology in enhancing diabetes management and cardiovascular health, marking a significant advancement in patient care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.